Saleh A Almenawer1, Jetan H Badhiwala1, Waleed Alhazzani1, Jeffrey Greenspoon1, Forough Farrokhyar1, Blake Yarascavitch1, Almunder Algird1, Edward Kachur1, Aleksa Cenic1, Waseem Sharieff1, Paula Klurfan1, Thorsteinn Gunnarsson1, Olufemi Ajani1, Kesava Reddy1, Sheila K Singh1, Naresh K Murty1. 1. Division of Neurosurgery, McMaster University, Hamilton, Ontario, Canada (S.A.A., A.A., E.K., A.C., P.K., T.G., O.A., K.R., S.K.S., N.K.M.); Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada (S.A.A., W.A., F.F.); Department of Medicine, McMaster University, Hamilton, Ontario, Canada (W.A.); Department of Oncology, McMaster University, Hamilton, Ontario, Canada (J.G.); Stem Cell and Cancer Research Institute, McMaster University, Hamilton, Ontario, Canada (S.K.S.); Division of Neurosurgery, University of Toronto, Toronto, Ontario, Canada (J.H.B.); Department of Radiation Oncology, Dalhousie University, Halifax, Nova Scotia, Canada (W.S.); Department of Neurological Surgery, University of Texas Southwestern Medical Center, Dallas, Texas (B.Y.).
Abstract
BACKGROUND: Optimal extent of surgical resection (EOR) of high-grade gliomas (HGGs) remains uncertain in the elderly given the unclear benefits and potentially higher rates of mortality and morbidity associated with more extensive degrees of resection. METHODS: We undertook a meta-analysis according to a predefined protocol and systematically searched literature databases for reports about HGG EOR. Elderly patients (≥60 y) undergoing biopsy, subtotal resection (STR), and gross total resection (GTR) were compared for the outcome measures of overall survival (OS), postoperative karnofsky performance status (KPS), progression-free survival (PFS), mortality, and morbidity. Treatment effects as pooled estimates, mean differences (MDs), or risk ratios (RRs) with corresponding 95% confidence intervals (CIs) were determined using random effects modeling. RESULTS: A total of 12 607 participants from 34 studies met eligibility criteria, including our current cohort of 211 patients. When comparing overall resection (of any extent) with biopsy, in favor of the resection group were OS (MD 3.88 mo, 95% CI: 2.14-5.62, P < .001), postoperative KPS (MD 10.4, 95% CI: 6.58-14.22, P < .001), PFS (MD 2.44 mo, 95% CI: 1.45-3.43, P < .001), mortality (RR = 0.27, 95% CI: 0.12-0.61, P = .002), and morbidity (RR = 0.82, 95% CI: 0.46-1.46, P = .514) . GTR was significantly superior to STR in terms of OS (MD 3.77 mo, 95% CI: 2.26-5.29, P < .001), postoperative KPS (MD 4.91, 95% CI: 0.91-8.92, P = .016), and PFS (MD 2.21 mo, 95% CI: 1.13-3.3, P < .001) with no difference in mortality (RR = 0.53, 95% CI: 0.05-5.71, P = .600) or morbidity (RR = 0.52, 95% CI: 0.18-1.49, P = .223). CONCLUSIONS: Our findings suggest an upward improvement in survival time, functional recovery, and tumor recurrence rate associated with increasing extents of safe resection. These benefits did not result in higher rates of mortality or morbidity if considered in conjunction with known established safety measures when managing elderly patients harboring HGGs.
BACKGROUND: Optimal extent of surgical resection (EOR) of high-grade gliomas (HGGs) remains uncertain in the elderly given the unclear benefits and potentially higher rates of mortality and morbidity associated with more extensive degrees of resection. METHODS: We undertook a meta-analysis according to a predefined protocol and systematically searched literature databases for reports about HGG EOR. Elderly patients (≥60 y) undergoing biopsy, subtotal resection (STR), and gross total resection (GTR) were compared for the outcome measures of overall survival (OS), postoperative karnofsky performance status (KPS), progression-free survival (PFS), mortality, and morbidity. Treatment effects as pooled estimates, mean differences (MDs), or risk ratios (RRs) with corresponding 95% confidence intervals (CIs) were determined using random effects modeling. RESULTS: A total of 12 607 participants from 34 studies met eligibility criteria, including our current cohort of 211 patients. When comparing overall resection (of any extent) with biopsy, in favor of the resection group were OS (MD 3.88 mo, 95% CI: 2.14-5.62, P < .001), postoperative KPS (MD 10.4, 95% CI: 6.58-14.22, P < .001), PFS (MD 2.44 mo, 95% CI: 1.45-3.43, P < .001), mortality (RR = 0.27, 95% CI: 0.12-0.61, P = .002), and morbidity (RR = 0.82, 95% CI: 0.46-1.46, P = .514) . GTR was significantly superior to STR in terms of OS (MD 3.77 mo, 95% CI: 2.26-5.29, P < .001), postoperative KPS (MD 4.91, 95% CI: 0.91-8.92, P = .016), and PFS (MD 2.21 mo, 95% CI: 1.13-3.3, P < .001) with no difference in mortality (RR = 0.53, 95% CI: 0.05-5.71, P = .600) or morbidity (RR = 0.52, 95% CI: 0.18-1.49, P = .223). CONCLUSIONS: Our findings suggest an upward improvement in survival time, functional recovery, and tumor recurrence rate associated with increasing extents of safe resection. These benefits did not result in higher rates of mortality or morbidity if considered in conjunction with known established safety measures when managing elderly patients harboring HGGs.
Authors: B Jeremic; Y Shibamoto; D Grujicic; B Milicic; M Stojanovic; N Nikolic; A Dagovic; J Aleksandrovic Journal: J Neurooncol Date: 1999-08 Impact factor: 4.130
Authors: Olivier-L Chinot; Maryline Barrie; Elisabeth Frauger; Henry Dufour; Dominique Figarella-Branger; Jacky Palmari; D Braguer; Khe Hoang-Xuan; Karima Moktari; Jean-Claude C Peragut; Pierre-Marie M Martin; François Grisoli Journal: Cancer Date: 2004-05-15 Impact factor: 6.860
Authors: Stephanie E Combs; Johanna Wagner; Marc Bischof; Thomas Welzel; Florian Wagner; Jürgen Debus; Daniela Schulz-Ertner Journal: Int J Radiat Oncol Biol Phys Date: 2007-10-29 Impact factor: 7.038
Authors: Jill S Barnholtz-Sloan; Vonetta L Williams; John L Maldonado; Dilip Shahani; Heather G Stockwell; Marc Chamberlain; Andrew E Sloan Journal: J Neurosurg Date: 2008-04 Impact factor: 5.115
Authors: Jayesh P Thawani; Ahmad Amirshaghaghi; Lesan Yan; Joel M Stein; Jessica Liu; Andrew Tsourkas Journal: Small Date: 2017-07-27 Impact factor: 13.281
Authors: Dieter Henrik Heiland; Gerrit Haaker; Ralf Watzlawick; Daniel Delev; Waseem Masalha; Pamela Franco; Marcia Machein; Ori Staszewski; Oliver Oelhke; Nils Henrik Nicolay; Oliver Schnell Journal: J Neurooncol Date: 2018-08-03 Impact factor: 4.130
Authors: Jacob S Young; Steven J Chmura; Derek A Wainwright; Bakhtiar Yamini; Katherine B Peters; Rimas V Lukas Journal: J Neurol Sci Date: 2017-08-01 Impact factor: 3.181